AI is no longer on the fringe of utility operations, it’s embedded in the field, in control rooms, and increasingly, in the ...

MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating at a breakneck pace since its launch earlier this year – and data from a new phase 3 study could give it a turbo boost.

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate's ...

Join us on Wednesday 1 October at 2pm for the first Happy By Nature Live Lesson - Forests with Steve Backshall live from The Lost Gardens of Heligan. In this interactive lesson, pupils will explore ...